Yu‐Fu Chen
Papers
1
Total Citations
12
H-Index
1
About
Yu-Fu Chen is a leading surgical oncologist whose research focuses on the aggressive management of peritoneal surface malignancies, particularly through cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). His major contribution lies in pioneering the application of this combined treatment for advanced peritoneal metastases of hepatocellular carcinoma (HCC-PM), a condition historically deemed untreatable. In his landmark 2020 study, Chen demonstrated that CRS/HIPEC can achieve significant survival benefits for select HCC-PM patients, challenging conventional therapeutic nihilism and establishing a new, potentially curative pathway. This work, which has garnered 12 citations, is notable for its rigorous patient selection criteria and detailed perioperative outcomes, providing a crucial evidence base for a previously neglected disease. Chen’s research is distinguished by its focus on translating complex, high-risk surgical techniques into viable strategies for rare metastatic presentations, directly impacting clinical guidelines and offering hope to patients with limited options. His ongoing investigations continue to refine patient selection and optimize multimodal protocols, cementing his reputation as a pioneer in expanding the frontiers of peritoneal oncology.
Research Focus
Key Achievements
Top Papers
- 1